Avexa Limited is an Australia-based biotechnology company with a focus on research and development of anti-infectives. The Company is developing drugs for the treatment of infectious diseases. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company was engaged in anti-infective pharmaceutical programs and projects. The Company operates in two segments: Research and Development, engaged in operation of conducting anti-infective research and development, and Listed investments, engaged in investing in the share market. The Company�s principal research programs focus on the discovery of medicines for the treatment of the diseases caused by human immunodeficiency virus (HIV) and vancomycin and methicillin-resistant bacteria. Apricitabine (ATC) is the Company�s nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection. HIV is the virus which causes acquired immunodeficiency syndrome (AIDS).